NSCLC

February 5, 2012

2012 Preview: Cancer Immunotherapy Catalysts

December 14, 2011 By MD Becker Partners 1 Comment

MD Becker Partners' Life Science Digest: 2012 graphic

2012 represents a period with robust news flow for emerging immuno-oncology companies

Filed Under: Articles Tagged With: AE37, AGEN, Agenus, Allovectin, Amgen, AMGN, Antigen Express, BAVA, Bavarian Nordic, BMY, Bristol-Myers Squibb, cancer vaccine, castrate-resistant prostate cancer, CELG, Celgene, Celldex Therapeutics, CLDX, cv-301, Dendreon, DNDN, Generex, GlaxoSmithKline, GlobeImmune, GNBT, gp100, GSK, HyperAcute, Idera Pharmaceuticals, IDRA, immunotherapy, IMO-2055, ipilimumab, Jennerex, JX-594, MAGE-A3, melanoma, NewLink Genetics, NLNK, NSCLC, Oncothyreon, OncoVex, ONTY, pancreatic cancer, panvac, PROSTVAC, Provenge, QS-21, sipuleucel-T, Stimuvax, TG4010, transgene, Vical, VICL, Yervoy

Cancer Immunotherapy: A Roundtable Discussion

June 30, 2011 By MD Becker Partners 3 Comments

meeting desk

Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.

Filed Under: Articles Tagged With: AGS-003, Allovectin-7, American Society of Clinical Oncology, Amgen, AMGN, AnGes, Argos Therapeutics, ASCO, AVAX Technologies, Bavarian Nordic, belagenpumatucel-L, BiovaxID, Biovest International, BLP25 liposome vaccine, BVTI, cancer immunotherapy, Cancer Research Institute, CDX-110, Celldex Therapeutics, CRI, GBM, GlaxoSmithKline, glioblastoma, GSK, Lucanix, MAGE-AS ASCI, melanoma, Merck KGA, MVA-MUC1-IL2, Novartis, Novarx, NSCLC, Oncothyreon, OncoVEX(GM-CSF), prostate cancer, PROSTVAC, rindopepimut, Stimuvax, TG4010, transgene, Vical, VICL

Cyclin-dependent Cancer Confab Preview

April 16, 2010 By MD Becker Partners Leave a Comment

cells

For more than a century, the American Association of Cancer Research [AACR] has held its annual meeting and this weekend will kick off the 101st event in Washington, DC, which is being held April 17-21, 2010. Many pharmaceutical and biotechnology companies will be presenting new data and approximately 6,300 abstracts will be discussed in oral [...]

Filed Under: Articles Tagged With: 2001 Nobel Prize in Physiology or Medicine, aacr, BAY 1000394, Bayer, biotechnology, BMS-387032, BMY, bristol-myers, cdk, cell cycle, CYCC, Cyclacel, cyclin E, cyclin-dependent kinase, dinaciclib, flavopiridol, k-ras, life science, NSCLC, oncology, PD-0332991, PFE, Pfizer, ras mutation, SCH 727965, seliciclib, SNS-032, SNSS, sunesis, TG02, Tragara Pharmaceuticals

Cancer Vaccine Therapies: Failures and Future Opportunities

April 7, 2010 By MD Becker Partners 3 Comments

FIGURE 1: FDA APPROVAL OF CANCER MABS FROM 1997-2010

(Note: the following text is an Executive Summary from our new 150-page report titled “Cancer Vaccine Therapies: Failures and Future Opportunities”) Since the early 1990s, cancer immunotherapy has provided hope to patients, physicians, and investors as a new treatment modality with limited side effects and superior efficacy. Cancer immunotherapy broadly includes passive immunization, active immunization, [...]

Filed Under: Articles Tagged With: active immunotherapy, AGEN, allogeneic, Allovectin-7, American Society for Clinical Oncology, Antigenics, Arzerra, ASCO, autologous, Bavarian Nordic, BIIB, Biogen Idec, Biologics License Application, biotechnology, BiovaxID, Biovest International, BMY, Bristol-Myers Squibb Company, BVTI, cancer vaccine, CD20, CDX-110, Celldex Therapeutics, CTLA-4, Dendreon, dendritic cells, DNDN, EGFRvIII, Genmab A/S, GlaxoSmithKline, GM-CSF, gp100, GSK, GVAX, immunotherapy, ipilimumab, life sciences, lung cancer, MAGE-3, MAGE-A3 ASCI, MD Becker Partners, melanoma, monoclonal antibodies, NCI, NHL, non-Hodgkin’s Lymphoma, NSCLC, ofatumumab, Oncophage, passive immunotherapy, PDUFA, PFE, Pfizer, prostate cancer, prostatic acid phosphatase, PROSTVAC, Provenge, RHHBY, Rituxan, rituximab, Roche Group, sipuleucel-T, TRICOM, vaccine, Vical, VICL